General Biotechnology

Two Systems, One Fight: How the Patent Dance and Orange Book Linkage Shape the $400 Billion Biologics War

Two Systems, One Fight: How the Patent Dance and Orange Book Linkage Are Shaping the $400B Biologics War
Biologics are no longer just “the next wave” of healthcare—they’re the battleground. With the global biologics market projected to reach roughly $4…

Two Systems, One Fight: How the Patent Dance and Orange Book Linkage Shape the $400 Billion Biologics War Read Post »

General Biotechnology

Find the Money Before the Patent Dies: How to Identify Out-Licensing Targets Near Drug Patent Expiry — and Capture Value That Most Companies Leave on the Table

Most pharma teams wait until the patent is already dying. That’s why they miss the money.
In drug development, timing is everything—but in licensing, timing is everything squared. The closer a product gets to patent expiry, the more value concentrates …

Find the Money Before the Patent Dies: How to Identify Out-Licensing Targets Near Drug Patent Expiry — and Capture Value That Most Companies Leave on the Table Read Post »

Biotechblog
Scroll to Top